Human immunodeficiency virus type 1 (HIV-1) infects a variety of cell types in cell cultures and in vivo (14, 24) . Two cell types which harbor HIV-1 in vivo are the CD4-positive T lymphocyte and the monocyte/macrophage (16, 17, 29, 45, 53) . Other cell types, including microvascular endothelial cells and astrocytic glial cells, may also be infected with HIV-1 in vivo (29, 41) .
Control of HIV-1 replication involves the binding of a variety of HIV-1-encoded proteins and cellular factors, which interact primarily with the long terminal repeat (LTR) on the 5' end of the provirus (for review, see reference 10). A virus-encoded transactivator of HIV-1 gene expression, Tat, binds to a section of viral RNA transcribed from the R region of the 5' LTR, TAR, and dramatically stimulates LTR-directed transcription and, possibly, posttranscriptional events (10, 47) . The HIV-1 protein Nef has been shown in some studies to downregulate HIV-1 replication, but this is extremely controversial (10) . The HIV-1 LTR has a variety of well-described and putative motifs which bind cellular factors and consequently affect transcriptional efficiency. The HIV-1 LTR contains a TATA box; three GCrich regions, which bind the SP1 transcription factor; and two 11-bp enhancer motifs, which bind nuclear factor KB (NF-KB) (10) . Each of these regions has been demonstrated to significantly affect HIV-1 replication (10) .
Many of the HIV-1 LTR protein-binding DNA motifs interact differently in various cellular milieus. For example, the three Spl sites appear to be necessary for viral replication only if activated NF-KB is not present in a particular intracellular environment (42) . NF-KB is important in the response of HIV-1 replication to a variety of exogenous stimuli (30) . This transcription factor appears to be a mem-* Corresponding author.
ber of a family of proteins related to the rel oncogene and has recently been cloned (21, 28, 35) . A well-characterized moiety of NF-KB is composed of two proteins, p50 and p65, bound as a heterodimer (35) . NF-KB is also bound to a repressor protein, IKB, in the cytoplasm. After stimulation by a variety of agents, including phorbol esters, tumor necrosis factor alpha, and lipopolysaccharide, and following antigenic stimulation, IKB is phosphorylated and dissociates from NF-KB (20, 38) . The unbound NF-KB is then transported to the nucleus, where it binds to enhancer regions of a wide variety of viral and cellular genes, including HIV-1. The activation of NF-KB, although important, may not be absolutely essential for HIV-1 replication within all cell types (31) .
The virally derived Tat protein, encoded from two exons in multiply spliced HIV-1-specific RNA, has been studied extensively and appears to be intimately tied to high levels of HIV-1 transcription (9, 15, 47) . Although Tat appears to increase HIV-1 transcription primarily by affecting elongation and possibly initiation of transcription (9, 15, 47) after binding to the RNA transcribed from the TAR region of the 5' LTR, in certain systems, a translational effect is also observed (e.g., Xenopus oocytes) (5). The TAR RNA has a complex stem-loop structure, with a proximal bulge in the stem (9) . Tat appears to bind to this bulge, and the results with Tat fusion proteins (i.e., with other RNA-or DNAbinding proteins) and substitution of a different binding motif for TAR have suggested that TAR functions merely to position Tat close to the 5' HIV-1 LTR (2, 3, 13, 44, 46, 49) .
A number of recent studies suggest that Tat, when bound to TAR, interacts with transcription factors bound to the NF-KB and Spl binding motifs (2, 32) . Nevertheless, there is also increasing evidence that another cellular factor(s) is necessary for the Tat-TAR effect on viral transcription. NOTES 7523 (e.g., a 345-amino-acid factor [18] , URBP-1 [19] , a 140-kDa TAR-stem binding protein [43] , and two factors which bind to the upper portion of the hairpin [TRP1 and TRP2] [48] ) and may be functionally important. A particularly well studied 68-kDa cellular factor which binds to the loop of TAR RNA has also been described (33) . In an important recent study, a cellular factor (TFIIS) involved in transcriptional elongation could complement the elongation-promoting activity of Tat on the HIV-1 LTR (26). Tat does not appear to function efficiently in murine cells, and this defect can be functionally complemented by human chromosome 12 (37) . Protein kinase C has also been demonstrated to be vital for the efficient functioning of Tat (25) . Thus, the interaction of the intracellular milieus with Tat function is clearly a key part of the mechanisms involved in the control of HIV-1 expression. Together, these diverse studies strongly point to a cellular cofactor(s) which is critical to Tat function in HIV-1 replication. Cell-specific control of HIV-1 transcription can also be inferred from these data.
To investigate the cell-specific control mechanisms of HIV-1 replication, we have studied HIV-1 expression in astrocytic glial cells, a cell type which may be important in HIV-1-induced central nervous system dysfunction in infected humans (41) . Our initial studies of astrocytic glial cells have suggested that TAR-independent expression of chloramphenicol acetyltransferase (CAT) from an HIV-1 LTR promoter occurs in certain astrocytic glial cells (50 (23) . These mutations disrupted base-pairing in the stem of TAR RNA. All plasmids were verified by sequencing to confirm proper construction.
These constructs were transiently transfected into unstimulated and phorbol ester (phorbol 12-myristate 13-acetate [PMA]; Sigma)-stimulated T-lymphocytic cells (H9), a monoblastoid cell line (U937), and U87-MG cells, of glioblastoma origin. The H9 and U937 cells were transfected by a DEAE-dextran method (38) , while the astrocytic cells were transfected by a calcium phosphate coprecipitation technique (1). Transfection efficiencies were standardized by cotransfection of a plasmid with the CAT gene downstream of the cytomegalovirus immediate-early promoter and subsequent determination of CAT activity in cellular extracts (39) . Virus production was measured by determination of HIV-1 p24 antigen levels in the supernatants with an enzyme-linked immunosorbent assay (ELISA; Du Pont) at 48 h posttransfection.
As illustrated in Fig. 1 , unstimulated H9 and U937 cells supported viral replication of the wild-type virus (HXB2) with an intact TAR but not of the three TAR mutant viruses. PMA stimulation of H9 and U937 cells did not affect wildtype viral growth but allowed viral expression by ATAR1 in H9 and U937 cells and of ATAR3 in H9 but not U937 cells ( Fig. 1A and B) . ATAR2, which contained the most severe disruption of TAR (SacI-Sacl deletion), was not viable in either cell line, with or without stimulation by PMA. Interestingly, wild-type HXB2 and all three TAR mutant viruses replicated in astrocytic glial cells (U87-MG) (Fig. 1C) . No augmentation in viral expression from any of these HIV-1 proviral constructs was demonstrated in U87-MG cells after PMA stimulation (Fig. 1C) . This pattern of TAR-independent viral replication was also demonstrated in a second unstimulated astrocytic glial cell line of glioblastoma origin (U138-MG) (data not illustrated). Of note, HIV-1 p24 antigen production in the astrocytic glial cell lines transfected with wild-type and TAR mutant viruses peaked at 48 h posttransfection and then plateaued over 10 days posttransfection. A continued rise in HIV-1 p24 antigen levels occurred over the 10 days posttransfection in the H9 and U937 cells transfected with wild-type virus (data not shown). The early plateau of HIV-1 p24 antigen levels in transfected astrocytic glial cells may be secondary to poor virus spread, as demonstrated previously (7, 22, 27) in cultures of these cells. These data therefore demonstrate Tar-independent HIV-1 replication in unstimulated astrocytic glial cells.
To further characterize TAR-independent viral replication in unstimulated glial cells, the patterns of HIV-1-specific RNA expression were evaluated in these transfections by Northern blot hybridization (40) . Wild-type expression of viral RNA, as characterized by nearly equivalent levels of unspliced (9.2-kb), singly spliced (4.3-kb), and multiply spliced (2-kb) HIV-1-specific RNA species (40), was demonstrated in unstimulated H9 and U87-MG cells (Fig. 2) . Wild-type patterns of HIV-1-specific RNA expression were also demonstrated in unstimulated astrocytic glial cells transfected with ATAR1 or ATAR2 (Fig. 2) . No viral RNA expression was demonstrated in unstimulated H9 cells transfected with ATAR1 or ATAR2 (Fig. 2) Fig. lA and B with 3A and B). Although the enhancer mutant virus replicated in astrocytic glial cells (U87-MG), the levels of HIV-1 p24 antigen detected in the supernatants were threeto fourfold lower than with the wild-type virus in U87-MG cells (compare Fig. 3C and Fig. 1C) . No augmentation in viral expression of the enhancer mutant was noted in any cell line with PMIA treatment (Fig. 3) . Interestingly, the proviral construct with mutations in both TAR (ATAR3 mutation) and the enhancer elements did not replicate in unstimulated or stimulated astrocytic glial cells (Fig. 3C) (Fig. 4 and data not  shown) .
To further evaluate the requirements for Tat in TARindependent replication within astrocytic glial cells, the Tat mutant virus with an intact TAR region and the ATARi and were transfected into U87-MG cells with various quantities of a Tat-expressing plasmid, pSV-Tat, which contains the first exon of tat downstream of a simian virus 40 promoter (36) . Increasing levels of viral replication were demonstrated with each proviral construct as increasing quantities of this Tat-expressing plasmid were added in cotransfection experiments with a standard quantity of the proviral constructs (Fig. 4) . Of note, an upper limit of and gradual decrease in viral production were demonstrated with increasing quantities of pSV-Tat with all proviral constructs evaluated (Fig.  4) . This plateau and possible biphasic effect of Tat in TAR-independent replication, as noted previously for TARdependent HIV-1 replication (15), will require further analyses. Therefore, Tat is demonstrated to be necessary for viral replication in these cells whether or not a functional TAR region is present in the virus.
Finally, as a further dramatic demonstration of TARindependent HIV-1 replication in unstimulated astrocytic glial cells, transfectants of U87-MG cells were fixed, stained, and evaluated for HIV-1-induced syncytium formation at 48 h posttransfection (Fig. 5 ). Significant numbers of multinucleated giant cells were observed after transfection of the three ATAR mutants and HXB2 (Fig. 5) . The syncytia were of the same approximate size and character in the TAR mutant and in the wild-type transfections. No syncytia were noted in transfections in which a plasmid without HIV-1 sequences was used (Fig. 5) . Fewer syncytia were observed in transfections with the enhancer mutant virus, and no syncytia were demonstrated in the transfections with the proviral construct with mutations in both TAR (ATAR3) and the enhancer motifs (Fig. 5 ).
These data demonstrate that TAR-independent HIV-1 replication is supported in certain cell types. Thus, TAR- infected (27) . The concept of proviral latency in astrocytic glial cells is complex. Human fetal glial cell explants have been demonstrated to pass through an early phase of productive HIV-1 infection and then remain in a state of low-level persistent infection (51) . In a preliminary study, it was suggested that latent HIV-1 infection in astrocytic cells may be secondary to increased expression of Nef (4). Nevertheless, in an important recent study, stable CD4 antigen transfections into neuroglioma cells allowed high levels of HIV-1 expression in these cells (52) . Thus, at least in some astrocytic lines, the spread and penetration of the virus within a culture may be a primary determinant of viral production.
If TAR-independent HIV-1 replication occurs in specific primary cells in infected individuals, this may have profound implications for the development of new therapies designed to combat clinical HIV-1 infection (14) . Further studies will be required to determine whether TAR-independent HIV-1 This work was supported in part by Public Health Service grants AI00930 (R.J.P.) and AI31836 (R.J.P.) and by a grant from the W. W. Smith Charitable Trust (R.J.P.).
